Pfizer, Inc. (PFE) Tops Q4 EPS by 3c; Cuts FY12 Outlook
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $25.26 -3.84%
EPS Growth %: -58.5%
Financial Fact:
Discontinued operations--net of tax: 0
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: -58.5%
Financial Fact:
Discontinued operations--net of tax: 0
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Pfizer, Inc. (NYSE: PFE) reported Q4 EPS of $0.50, $0.03 better than the analyst estimate of $0.47. Revenue for the quarter came in at $16.7 billion versus the consensus estimate of $16.61 billion.
Lowered its FY12 non-GAAP EPS guidance from $2.25-$2.35 to $2.20-$2.30, which compares to the Street estimate of $2.30.
For earnings history and earnings-related data on Pfizer, Inc. (PFE) click here.
Lowered its FY12 non-GAAP EPS guidance from $2.25-$2.35 to $2.20-$2.30, which compares to the Street estimate of $2.30.
For earnings history and earnings-related data on Pfizer, Inc. (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Terex (TEX) Tops Q1 EPS by 24c, provides guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Guidance, Hot ListRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
